Nuvation Bio Reports Over 200 New Patient Starts, Targets $150M Revenue
Nuvation Bio reports over 200 new patient starts per quarter for Erozi, driven by rising first-line use and plans to capture a majority of high-grade disease patients to meet a $150 million consensus revenue mark. Phase 3 enrollment remains on track for a 2029 readout with no interim analysis planned.
1. Patient Uptake and Revenue Outlook
Nuvation Bio has achieved over 200 new patient starts per quarter for Erozi, with the majority in later-line therapy but a growing share moving to first-line use. Management expressed confidence in capturing a significant patient base to support a $150 million consensus revenue target for 2026.
2. Phase 3 Trial Enrollment
The ongoing phase 3 progression-free survival study is enrolling as expected, with no plans for an interim analysis. The trial is projected to reach the required number of events for a 2029 completion, reflecting the time needed for PFS measurement.
3. Seasonal and Payer Dynamics
Usage dipped somewhat in the fourth quarter, and management noted uncertainty around a seasonal bounceback in Q1. The company is monitoring payer dynamics closely but remains confident in consistent new patient diagnoses and treatment starts.
4. Competitor Entry and Guideline Impact
A competitor is expected to enter the market later this year, but Nuvation Bio highlighted its unmatched duration of response and tolerability profile for Erozi. Recent NCCN guideline changes have already boosted TKI prescriptions and are anticipated to drive further first-line adoption.